Segment & Geographic Data
Quant-Grade Normalized Data
API & CSV Delivery
Scholar Rock Holding's Business Segments
Scholar Rock Holding's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q3 FY2026
Reportable Segments
1
Largest Segment
Single Reportable Segment
Total Revenue
$ 1
Regions Reported
-
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/SRRK/segments
https://api.csimarket.com/api/v1/companies/SRRK/geographic
https://api.csimarket.com/api/v1/companies/SRRK/exposure
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Revenue Share by Reportable Segment - Q3 FY2026
- Single Reportable Segment100%
Revenue by Reportable Segment - Q3 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Reportable Segment | $ 1 | 100% |
Revenue by Product & Service Category - Q3 FY2026
- Isembyld0%
Revenue by Product & Service Category - Q3 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Isembyld | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Scholar Rock Holding
Scholar Rock Holding Corp is a clinical-stage biopharmaceutical company that focuses on discovering and developing a new class of medicines called
icotinamide adenine dinucleotide (NAD+)-based medicines. The company's primary goal is to develop innovative treatments for patients suffering from serious diseases in which the tissue microenvironment plays a significant role.
The company's research and development efforts are centered on the understanding of the biology underlying the growth and remodeling of tissues and the role of growth factors in this process. Scholar Rock utilizes their expertise in transforming the fundamental understanding of TGFβ superfamily activation to develop therapeutic candidates that selectively target disease-causing signaling proteins.
Scholar Rock's proprietary platform is based on the scientific discoveries made by the company's founders, which include the identification of hidden sterically restricted epitopes (HSREs) within the extracellular matrix (ECM). These HSREs play a crucial role in regulating the activation of various growth factors, including TGFβ superfamily ligands.
The company has developed a unique drug discovery and development approach called Scholarly Targeted Therapeutics (STT), which enables the selective targeting of specific growth factors while sparing others. By focusing on specific HSREs, Scholar Rock aims to develop therapeutic candidates that can modulate the activity of disease-causing growth factors, leading to the restoration of tissue homeostasis.
Scholar Rock's lead product candidate, SRK-015, is being developed to treat patients with Spinal Muscular Atrophy (SMA). SMA is a genetic neuromuscular disorder characterized by the loss of motor neurons, resulting in muscle weakness and progressive paralysis. SRK-015 is designed to selectively inhibit the activation of myostatin, a growth factor that restricts muscle growth and regeneration. By inhibiting myostatin, SRK-015 has the potential to enhance muscle strength and motor function in SMA patients.
In addition to SMA, Scholar Rock is also exploring other therapeutic areas, including oncology, fibrosis, and immuno-oncology, where the dysregulation of growth factors plays a crucial role. The company aims to leverage its unique drug discovery platform to develop innovative therapies for patients suffering from these and other serious diseases.
Overall, Scholar Rock Holding Corp is a pioneering biopharmaceutical company that is focused on developing novel NAD+-based medicines that selectively target disease-causing signaling proteins. Through their innovative research and development efforts, the company aims to provide innovative treatment options for patients suffering from a range of serious diseases.
icotinamide adenine dinucleotide (NAD+)-based medicines. The company's primary goal is to develop innovative treatments for patients suffering from serious diseases in which the tissue microenvironment plays a significant role.
The company's research and development efforts are centered on the understanding of the biology underlying the growth and remodeling of tissues and the role of growth factors in this process. Scholar Rock utilizes their expertise in transforming the fundamental understanding of TGFβ superfamily activation to develop therapeutic candidates that selectively target disease-causing signaling proteins.
Scholar Rock's proprietary platform is based on the scientific discoveries made by the company's founders, which include the identification of hidden sterically restricted epitopes (HSREs) within the extracellular matrix (ECM). These HSREs play a crucial role in regulating the activation of various growth factors, including TGFβ superfamily ligands.
The company has developed a unique drug discovery and development approach called Scholarly Targeted Therapeutics (STT), which enables the selective targeting of specific growth factors while sparing others. By focusing on specific HSREs, Scholar Rock aims to develop therapeutic candidates that can modulate the activity of disease-causing growth factors, leading to the restoration of tissue homeostasis.
Scholar Rock's lead product candidate, SRK-015, is being developed to treat patients with Spinal Muscular Atrophy (SMA). SMA is a genetic neuromuscular disorder characterized by the loss of motor neurons, resulting in muscle weakness and progressive paralysis. SRK-015 is designed to selectively inhibit the activation of myostatin, a growth factor that restricts muscle growth and regeneration. By inhibiting myostatin, SRK-015 has the potential to enhance muscle strength and motor function in SMA patients.
In addition to SMA, Scholar Rock is also exploring other therapeutic areas, including oncology, fibrosis, and immuno-oncology, where the dysregulation of growth factors plays a crucial role. The company aims to leverage its unique drug discovery platform to develop innovative therapies for patients suffering from these and other serious diseases.
Overall, Scholar Rock Holding Corp is a pioneering biopharmaceutical company that is focused on developing novel NAD+-based medicines that selectively target disease-causing signaling proteins. Through their innovative research and development efforts, the company aims to provide innovative treatment options for patients suffering from a range of serious diseases.
Scholar Rock Holding Corp Overview
Scholar Rock Holding Corp is a clinical-stage biopharmaceutical company that specializes in the discovery and development of innovative therapeutics aimed at treating serious diseases. The companys focus is on addressing debilitating disorders within the musculoskeletal, neurological, and immune systems. By engaging in advanced research and development, Scholar Rock aims to fulfill unmet medical needs through its various segments, product candidates, and services.
Segments
1. Musculoskeletal Segment
- Lead Product Candidate: SRK-015
- SRK-015 is a highly selective inhibitor targeting the activation of myostatin, which is a protein that plays a critical role in regulating muscle growth negatively. By inhibiting myostatin activation, SRK-015 is designed to promote muscle strength and enhance motor function in patients afflicted with rare neuromuscular conditions such as Spinal Muscular Atrophy (SMA) and Amyotrophic Lateral Sclerosis (ALS).
- Clinical Progress: Preclinical studies have shown promise in improving muscle function and strength, and clinical trials have been initiated to further elucidate the drugs efficacy and safety profile.
- Other Musculoskeletal Programs
- Scholar Rock is also engaged in several preclinical programs aimed at exploring additional pathways related to muscle biology and regeneration. These programs are intended to develop therapies for a range of musculoskeletal disorders and conditions characterized by muscle wasting. The goal is to create targeted treatments that can improve the quality of life for patients suffering from these debilitating diseases.
2. Neurological Segment
- Lead Product Candidate: Undisclosed
- Although specific details remain under wraps, Scholar Rock is developing a product candidate specifically aimed at neurological disorders. This candidate operates through modulation of certain signaling pathways that are pivotal in neuronal function and health.
- Other Neurological Programs
- The company is actively pursuing research and development efforts to identify and create novel therapeutics that tackle various neurological disorders, particularly neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. These programs focus on mechanisms that can potentially slow down or alter the course of these diseases, providing hope for affected individuals and their families.
3. Immune Segment
- Lead Product Candidate: Undisclosed
- In the immune segment, Scholar Rock is developing therapies aimed at autoimmune and inflammatory diseases. While specific details about the candidate are not currently available, the focus is on innovative approaches that modulate the immune response.
- Other Immune Programs
- Scholar Rock is also engaged in the discovery and development of additional immunotherapies to target a range of immune-mediated diseases. These programs prioritize finding the right balance between inflammation and immune system regulation, aiming to develop therapies that provide effective treatment with minimal side effects.
Services Provided
Scholar Rock Holding Corp does not only focus on drug development; it also offers a variety of services rooted in its extensive expertise in therapeutic discovery, which includes:
- Drug Discovery and Development: Utilizing cutting-edge technologies and methodological approaches, Scholar Rock identifies and advances potential drug candidates through various stages of preclinical and clinical development. Their process includes high-throughput screening, lead optimization, and early clinical evaluation.
- Research Collaborations: The company actively engages in collaborative research efforts with academic institutions, research organizations, and industry partners. These collaborations facilitate a comprehensive understanding of pertinent disease pathways and foster the development of innovative therapeutic interventions.
By effectively leveraging its insights in biopharmaceutical research and development, Scholar Rock aims to deliver breakthrough therapies that significantly improve patient outcomes and enhance the quality of life for individuals affected by challenging disorders in the musculoskeletal, neurological, and immune systems. Through its innovative programs and dedicated services, the company positions itself as a leader in addressing critical health challenges.
Scholar Rock Holding Corp is a clinical-stage biopharmaceutical company that specializes in the discovery and development of innovative therapeutics aimed at treating serious diseases. The companys focus is on addressing debilitating disorders within the musculoskeletal, neurological, and immune systems. By engaging in advanced research and development, Scholar Rock aims to fulfill unmet medical needs through its various segments, product candidates, and services.
Segments
1. Musculoskeletal Segment
- Lead Product Candidate: SRK-015
- SRK-015 is a highly selective inhibitor targeting the activation of myostatin, which is a protein that plays a critical role in regulating muscle growth negatively. By inhibiting myostatin activation, SRK-015 is designed to promote muscle strength and enhance motor function in patients afflicted with rare neuromuscular conditions such as Spinal Muscular Atrophy (SMA) and Amyotrophic Lateral Sclerosis (ALS).
- Clinical Progress: Preclinical studies have shown promise in improving muscle function and strength, and clinical trials have been initiated to further elucidate the drugs efficacy and safety profile.
- Other Musculoskeletal Programs
- Scholar Rock is also engaged in several preclinical programs aimed at exploring additional pathways related to muscle biology and regeneration. These programs are intended to develop therapies for a range of musculoskeletal disorders and conditions characterized by muscle wasting. The goal is to create targeted treatments that can improve the quality of life for patients suffering from these debilitating diseases.
2. Neurological Segment
- Lead Product Candidate: Undisclosed
- Although specific details remain under wraps, Scholar Rock is developing a product candidate specifically aimed at neurological disorders. This candidate operates through modulation of certain signaling pathways that are pivotal in neuronal function and health.
- Other Neurological Programs
- The company is actively pursuing research and development efforts to identify and create novel therapeutics that tackle various neurological disorders, particularly neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease, and Huntington’s disease. These programs focus on mechanisms that can potentially slow down or alter the course of these diseases, providing hope for affected individuals and their families.
3. Immune Segment
- Lead Product Candidate: Undisclosed
- In the immune segment, Scholar Rock is developing therapies aimed at autoimmune and inflammatory diseases. While specific details about the candidate are not currently available, the focus is on innovative approaches that modulate the immune response.
- Other Immune Programs
- Scholar Rock is also engaged in the discovery and development of additional immunotherapies to target a range of immune-mediated diseases. These programs prioritize finding the right balance between inflammation and immune system regulation, aiming to develop therapies that provide effective treatment with minimal side effects.
Services Provided
Scholar Rock Holding Corp does not only focus on drug development; it also offers a variety of services rooted in its extensive expertise in therapeutic discovery, which includes:
- Drug Discovery and Development: Utilizing cutting-edge technologies and methodological approaches, Scholar Rock identifies and advances potential drug candidates through various stages of preclinical and clinical development. Their process includes high-throughput screening, lead optimization, and early clinical evaluation.
- Research Collaborations: The company actively engages in collaborative research efforts with academic institutions, research organizations, and industry partners. These collaborations facilitate a comprehensive understanding of pertinent disease pathways and foster the development of innovative therapeutic interventions.
By effectively leveraging its insights in biopharmaceutical research and development, Scholar Rock aims to deliver breakthrough therapies that significantly improve patient outcomes and enhance the quality of life for individuals affected by challenging disorders in the musculoskeletal, neurological, and immune systems. Through its innovative programs and dedicated services, the company positions itself as a leader in addressing critical health challenges.